The Global Iliac Stent Market size is expected to reach $1.4 billion by 2030, rising at a market growth of 5.9% CAGR during the forecast period.
North America has a significant prevalence of PAD. Therefore, the North America region captured $400.0 million revenue in the market in 2022. The incidence of PAD is predicted to climb with age and the prevalence of risk factors like diabetes and obesity rising, which will fuel the need for iliac stents as the main treatment option for revascularization and symptom relief.
PAD is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs, most commonly affecting the lower extremities. It affects a large population worldwide, particularly among older adults and individuals with risk factors such as smoking, diabetes, hypertension, and dyslipidemia. Hence, the prevalence of peripheral artery disease is propelling the market’s growth.
Aging is one of the major risk factors for vascular diseases such as PAD, which commonly affects the iliac arteries. As individuals age, the walls of their blood vessels may become thicker and less elastic, leading to plaque buildup and arteries narrowing. Therefore, the increasing aging population is driving the growth of the market.
However, the cost of iliac stent placement includes various components, such as the price of the stent device, hospital fees, physician fees, anesthesia costs, imaging studies, medications, and follow-up care. These expenses can add to a substantial financial burden for patients and healthcare systems, particularly in cases where multiple stents are required, or complications arise during the procedure. Thus, the high cost of treatment is hampering the market’s growth.
During the height of the pandemic, many elective medical procedures, including those related to peripheral artery disease (PAD) and iliac stenting, were postponed or canceled to conserve healthcare resources and reduce the risk of viral transmission. This temporarily decreased procedural volumes and revenue for manufacturers and healthcare providers in the market. Thus, the COVID-19 pandemic had a negative impact on the market.
North America has a significant prevalence of PAD. Therefore, the North America region captured $400.0 million revenue in the market in 2022. The incidence of PAD is predicted to climb with age and the prevalence of risk factors like diabetes and obesity rising, which will fuel the need for iliac stents as the main treatment option for revascularization and symptom relief.
PAD is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs, most commonly affecting the lower extremities. It affects a large population worldwide, particularly among older adults and individuals with risk factors such as smoking, diabetes, hypertension, and dyslipidemia. Hence, the prevalence of peripheral artery disease is propelling the market’s growth.
Aging is one of the major risk factors for vascular diseases such as PAD, which commonly affects the iliac arteries. As individuals age, the walls of their blood vessels may become thicker and less elastic, leading to plaque buildup and arteries narrowing. Therefore, the increasing aging population is driving the growth of the market.
However, the cost of iliac stent placement includes various components, such as the price of the stent device, hospital fees, physician fees, anesthesia costs, imaging studies, medications, and follow-up care. These expenses can add to a substantial financial burden for patients and healthcare systems, particularly in cases where multiple stents are required, or complications arise during the procedure. Thus, the high cost of treatment is hampering the market’s growth.
During the height of the pandemic, many elective medical procedures, including those related to peripheral artery disease (PAD) and iliac stenting, were postponed or canceled to conserve healthcare resources and reduce the risk of viral transmission. This temporarily decreased procedural volumes and revenue for manufacturers and healthcare providers in the market. Thus, the COVID-19 pandemic had a negative impact on the market.
By Artery Lesions Analysis
On the basis of artery lesions, the market is segmented into common iliac artery lesions, severe calcified lesions, and complete obstructive lesions. The common iliac artery lesions segment recorded 60.6% revenue share in the market in 2022. Common iliac artery lesions have significant clinical implications, as they can compromise blood flow to both the internal and external iliac arteries, affecting perfusion to the pelvis, lower extremities, and vital organs.By End-use Analysis
Based on end-use, the market is categorized into hospitals, outpatient facilities, and others. The outpatient facilities segment witnessed 26.7% revenue share in the market in 2022. Outpatient facilities offer a more comfortable and convenient environment for patients undergoing vascular interventions like iliac stent placement.
By Type Analysis
Based on type, the market is divided into self-expandable stents, balloon-expandable stents, and others. In 2022, the self-expandable stents segment garnered 62.3% revenue share in the market. Self-expandable stents are designed to be flexible and conformable, allowing for precise deployment and adaptation to the shape and curvature of the iliac arteries.By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated 22.6% revenue share in the market in 2022. Urbanization and lifestyle changes in the Asia Pacific region have led to the adoption of Westernized lifestyles characterized by physical inactivity, unhealthy dietary habits, and increased prevalence of risk factors for cardiovascular diseases.List of Key Companies Profiled
- Becton, Dickinson and Company
- Abbott Laboratories
- Boston Scientific Corporation
- W.L. Gore & Associates, Inc.
- Medtronic PLC
- Cook Medical, Inc.(Cook Group)
- Terumo Corporation
- iVascular S.L.U.
- Getinge AB
- Biotronik SE & Co. KG
Market Report Segmentation
By Artery Lesions- Common Iliac Artery Lesions
- Severe Calcified Lesions
- Complete Obstructive Lesions
- Hospitals
- Outpatient Facilities
- Others
- Self-expandable Stents
- Balloon-expandable Stents
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Iliac Stent Market by Artery Lesions
Chapter 5. Global Iliac Stent Market by End-use
Chapter 6. Global Iliac Stent Market by Type
Chapter 7. Global Iliac Stent Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Becton, Dickinson and Company
- Abbott Laboratories
- Boston Scientific Corporation
- W. L. Gore & Associates, Inc.
- Medtronic PLC
- Cook Medical, Inc.(Cook Group)
- Terumo Corporation
- iVascular S.L.U.
- Getinge AB
- Biotronik SE & Co. KG
Methodology
LOADING...
